Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
90 participants
INTERVENTIONAL
2008-10-31
2012-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of the Timing of Colloid and Crystalloid Infusions on Postspinal Hypotension After Spinal Anesthesia for Caesarian Section
NCT02680678
Colloid Preload Versus Crystalloid Co-load in Cesarean Section Under Spinal Anesthesia
NCT03107598
Comparison of Hydroxyethyl Starch and Crystalloid Coload Combined With Norepinephrine Infusion for Hypotension
NCT05475990
Combined Colloid Preload And Crystalloid Coload Versus Crystalloid Coload During Spinal Anesthesia for Cesarean Delivery
NCT02961842
Colloid Pre-Loading on D-Dimer During Cesarean Section Under Spinal Anesthesia
NCT02622126
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Methods: We studied 90 women with uncomplicated pregnancies undergoing elective caesarean section under spinal anaesthesia. Intravenous access was established in all with two peripheral intravenous lines, the first being used for the baseline volume infusion. Immediately after induction of spinal anaesthesia, Lactated Ringer's solution (Group L) or HES (Group C) infusions were started at the maximal possible rate via the second line in groups L and C respectively. The third group (Group E) patients received lactated Ringer's solution at a 'keep vein open' rate to maintain the double-blind nature. The incidence of hypotension, ephedrine requirements, total amount of volume and side effects were recorded.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
No coloading (Group E)
Placebo comparator
Cristalloid and colloid coloading
Cristalloid coloading (Group L) Colloid coloading (Group C) No coloading (Group E)Placebo Comparator
Cristalloid (Lactated Ringer) Coloading
Cristalloid (Lactated Ringer's) Coloading (Group L)
Cristalloid and colloid coloading
Cristalloid coloading (Group L) Colloid coloading (Group C) No coloading (Group E)Placebo Comparator
Colloid (HES) coloading
Colloid (HES) coloading (Group C)
Cristalloid and colloid coloading
Cristalloid coloading (Group L) Colloid coloading (Group C) No coloading (Group E)Placebo Comparator
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cristalloid and colloid coloading
Cristalloid coloading (Group L) Colloid coloading (Group C) No coloading (Group E)Placebo Comparator
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Pregnancy preinduced hypertension,
* Being in active labour or requiring emergency caesarean section,
* Any contraindication to regional anaesthesia such as local infection or bleeding disorders.
19 Years
46 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cukurova University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hakki Unlugenc
Prof Dr.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hakki Unlugenc, Prof Dr
Role: STUDY_CHAIR
Cukurova University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hakki Unlugenc
Adana, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Cukurova University
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HZLTNS97
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.